JF
RNAM

Jump Financial’s Avidity Biosciences RNAM Stock Holding History

Jump Financial’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-95,575
Closed -$2.78M – 1959
2024
Q4 		$2.78M Buy
+95,575
New +$3.99M 0.06% 420
2024
Q1 		– Sell
-70,594
Closed -$639K – 2239
2023
Q4 		$639K Sell
70,594
-40,093
-36% -$268K 0.02% 929
2023
Q3 		$706K Buy
110,687
+13,768
+14% +$119K 0.03% 832
2023
Q2 		$1.07M Buy
+96,919
New +$1.22M 0.04% 648
2023
Q1 		– Sell
-11,695
Closed -$260K – 1983
2022
Q4 		$260K Buy
+11,695
New +$174K 0.01% 1126

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jump Financial's RNAM Position: Q1 2025 in Review

Jump Financial sold out of Avidity Biosciences (RNAM) in Q1 2025, closing a stake of 95,575 shares — an estimated $2.78M sold.

Jump Financial first reported a position in RNAM in Q4 2022 and held it in 5 quarters. The position peaked at $2.78M in Q4 2024. 220 funds tracked by Wall St. Rank hold RNAM as of Q1 2025.

  • Jump Financial reported no remaining Avidity Biosciences position as of Q1 2025 after selling out during the quarter.
  • Jump Financial sold 95,575 Avidity Biosciences shares in Q1 2025, an estimated $2.78M.
  • Jump Financial first reported a position in Avidity Biosciences in Q4 2022 and held it in 5 quarters.
  • Jump Financial's Avidity Biosciences position peaked at $2.78M in Q4 2024.
  • 220 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2025.

Based on Jump Financial's 13F filing for Q1 2025, filed 14 May 2025.